2nd Inflammatory Skin Disease Summit
The Translational Revolution

November 16–19, 2016
The New York Academy of Medicine, NY, USA
Scientific Program

WEDNESDAY, NOVEMBER 16, 2016

02.30 pm REGISTRATION OPENS

Opening
Chairs: Emma Guttman (New York, NY), Patrick M. Brunner (New York, NY)

03.30 pm – 03.45 pm Welcome address

03.45 pm – 04.00 pm Setting the stage
Georg Stingl (Vienna, Austria)

04.00 pm – 04.30 pm Inflammatory skin diseases - The technological revolution
James G. Krueger (New York, NY)

04.30 pm – 05.00 pm The skin immune system in health and disease
Thomas S. Kupper (Boston, MA)

05.00 pm – 05.15 pm BREAK

05.15 pm – 06.45 pm Sponsored afternoon symposium (see page 9)

06.45 pm – 07.30 pm Oral presentations from selected abstracts
Chairs: Amos Gilhar (Haifa, IL), Avi Ma'ayan (New York, NY)

06.45pm – 06.57 pm P074: A distinct molecular signature of interface dermatitis as determined by gene expression analysis combined with disease independent histological phenotyping
Felix Lauffer (Munich, Germany)

06.57 pm – 07.09 pm P126: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk markers
Patrick M. Brunner (New York, NY)

07.09 pm – 07.21 pm P046: CD8+ polycytotoxic T cells are defined by natural killer cell receptors and exhibit antimicrobial activity against intracellular bacteria
Samuel J. Balin, Los Angeles, CA

07.30 pm – 09.30 pm RECEPTION AND POSTER VIEWING
07.00 am – 08.00 am REGISTRATION AND CONTINENTAL BREAKFAST

08.00 am – 09.30 am Sponsored breakfast symposium (see pages 10)

Morning lectures
Chairs: Robert Modlin (Los Angeles, CA), Miriam Merad (New York, NY)

09.30 am – 10.00 am Innate immunity and dendritic cells
Michel Gilliet (Lausanne, Switzerland)

10.00 am – 10.30 am Antigen presentation in the skin
Keisuke C. Nagao (Bethesda, MD)

10.30 am – 11.00 am Dendritic cell subsets - Of mice and men
Eynav Klechevsky (St. Louis, MO)

11.00 am – 11.30 am COFFEE BREAK

Chairs: Johann Gudjonsson (Ann Arbor, MI), Claudia Traidl-Hoffmann (Augsburg, Germany)

11.30 am – 12.00 pm Skin T cells revisited
Rachael A. Clark (Boston, MA)

12.00 pm – 12.30 pm Lymphocyte identity crisis: genomic views
John O’Shea (Bethesda, MD)

12.30 pm – 12.45 pm BREAK

12.45 pm – 02.15 pm Satellite lunch symposium (see page 10)

Afternoon lectures
Chairs: Richard D. Granstein (New York, NY), Lawrence F. Eichenfield (San Diego, CA)

02.15 pm – 02.45 pm The microbiome of healthy and eczematous skin
Heidi Kong (Bethesda, MD)

02.45 pm – 03.15 pm Rosacea and AMPs
Richard Gallo (San Diego, CA)

03.15 pm – 03.45 pm Acne and hidradenitis
Diane M. Thiboutot (Hershey, PA)

03.45 pm – 04.15 pm Role of infections in inflammatory skin diseases
Donald Y. M. Leung (Denver, CO)
4.15 pm – 04.45 pm  COFFEE BREAK

Chairs: Michelle Lowes (New York, NY), Hugh Sampson (New York, NY)

04.45 pm – 05.15 pm  The inflammasome and autoinflammation
Raphaela T. Goldbach-Mansky (Bethesda, MD)

05.15 pm – 05.45 pm  Skin inflammation by 3-dimensional imaging
Kenji Kabashima (Kyoto, Japan)

05.45 pm – 06.15 pm  Mediators of inflammation
Thomas Luger (Münster, Germany)

06.15 pm – 09.00 pm  RECEPTION AND POSTER VIEWING
FRIDAY, NOVEMBER 18, 2016

07.30 am – 08.30 am  REGISTRATION AND CONTINENTAL BREAKFAST

Morning lectures
Chairs: Lisa A. Beck (Rochester, NY), David E. Cohen (New York, NY)

08.30 am – 09.00 am  Comorbidities in inflammatory skin diseases
Jonathan I. Silverberg (Chicago, IL)

09.00 am – 09.30 am  Psoriasis - State of the art mechanisms, targeted therapies and future developments
Frank O. Nestle (Cambridge, MA)

09.30 am – 10.00 am  Monocyte/myeloid cell dysfunction in psoriasis – relationship to comorbidity mechanisms
Kevin D. Cooper (Cleveland, OH)

10.00 am – 10.30 am  COFFEE BREAK

Chairs: Nicole L. Ward (Cleveland, OH), Keith Choate (New Haven, CT)

10.30 am – 11.00 am  Evolving concepts in atopic dermatitis and implications for targeted therapeutics
Emma Guttman (New York, NY)

11.00 am – 11.30 am  Translational potential for treatment of pediatric inflammatory skin diseases
Amy S. Paller (Chicago, IL)

11.30 am – 12.00 pm  Adverse cutaneous drug reactions – Clinical presentation and pathogenesis
Lars E. French (Zurich, Switzerland)

12.00 pm – 12.15 pm  BREAK

12.15 pm – 01.45 pm  Sponsored lunch symposium (see pages 10)

Afternoon lectures
Chairs: Andrew Alexis (New York, NY), David A. Norris (Denver, CO)

01.45 pm – 02.15 pm  Translational research in vitiligo - Launching a new era of targeted treatment
John E. Harris (Worcester, MA)
02.15 pm - 02.45 pm  Targeted therapies in alopecia areata  
Angela Christiano (New York, NY)

02.45 pm - 03.15 pm  Characterization of the autoantibody repertoire in pemphigus  
John R. Stanley (Philadelphia, PA)

03.15 pm - 03.45 pm  Targeted therapy for blistering disorders  
Aimee S. Payne (Philadelphia, PA)

03.45 pm - 04.00 pm  COFFEE BREAK

04.00 pm - 05.30 pm  Sponsored afternoon symposium (see page 11)
SATURDAY, NOVEMBER 19, 2016

07.30 am – 08.30 am  REGISTRATION AND CONTINENTAL BREAKFAST

08.30 am – 10.00 am  Sponsored breakfast symposium (see page 12)

Morning lectures
Chairs: Emmilia Hodak (Tel Aviv, Israel), Mayte Suárez-Fariñas (New York, NY)

10.00 am – 10.30 am  Inflammation and cancer – The two sides of the coin
Martin Röcken (Tübingen, Germany)

10.30 am – 11.00 am  Sarcoidosis and targeted therapeutics
Misha A. Rosenbach (Philadelphia, PA)

11.00 am – 12.00 pm  Oral presentations from selected abstracts
Chairs: Ralf Paus (Manchester, United Kingdom), Stefanie Eyerich (Munich, Germany)

11.00 am – 11.12 am  P122: Dupilumab progressively suppresses inflammation, reduces epidermal hyperplasia and increases epidermal barrier gene expression in atopic dermatitis (AD) skin
Emma Guttman (New York, NY)

11.12 am – 11.24 am  P087: Novel chimeric immunoreceptors for pemphigus vulgaris (PV) therapy
Christoph T. Ellebrecht (Philadelphia, PA)

11.24 am – 11.36 am  P048: Streptococcus pyogenes activation of circulating CLA+ T cells in guttate and chronic plaque psoriasis patients: IL-9 production dependence on time of flare, PASI, ASO levels, and relationship with IL-17 response
Luis F Santamaria-Babí (Barcelona, Spain)

11.36 am – 11.48 am  P111: The epithelial DLX3-dependent transcriptome regulates skin immune homeostasis
Shreya Bhattacharya (Bethesda, MD)

11.48 am – 12.00 pm  P018: Application of peanut protein on normal skin leads to tolerance whereas application on irritated skin leads to IgE sensitization
Lucie Mondoulet (Montrouge, France)

12.00 pm – 12.15 pm  BREAK
12.15 pm – 01.45 pm  **Oral presentations from selected abstracts**  
*Chairs: Kilian Eyerich (Munich, Germany), Christine Bangert (Vienna, Austria)*

12.15 pm - 12.27 pm  
P107: Altered composition of epidermal lipids correlates with Staphylococcus aureus colonization status in adult Atopic Dermatitis subjects  
*Arup Indra (Corvallis, OR)*

12.27 pm - 12.39 pm  
P021: Association between atopic dermatitis and autoimmune disease in adults  
*Yuki M.F. Andersen (Hellerup, Denmark)*

12.39 pm - 12.51 pm  
P004: Clinical and Histologic Patterns of Dermatologic Toxicity from Immune Checkpoint Blockade Therapy  
*Jonathan Curry (Houston, TX)*

12.51 pm - 01.03 pm  
P058: Immunological analysis of metastatic melanoma patients treated with nivolumab; is Th9 cell subset a possible biomarker of treatment efficacy?  
*Yumi Nonomura (Kyoto, Japan)*

01.03 pm – 01.15 pm  
P125: Anti-inflammatory activity of a bacterial small molecule product derives from Aryl Hydrocarbon Receptor activation  
*Susan Smith (Durham, NC)*

01.15 pm – 01.27 pm  
P127: Precision medicine in psoriasis: Machine learning and proteomics join forces to develop a blood-based test to predict response to tofacitinib or Etanercept in psoriasis patients  
*Mayte Suárez-Fariñas (New York, US)*

01.27 pm – 01.39 pm  
P012: Improvement of DC vaccination strategies: Identification of a stable and migratory subset of IL-10 modulated dendritic cells.  
*Verena Raker (Mainz, Germany)*

**Afternoon lectures**  
*Chairs: Daniel Mimouni (Tel Aviv, Israel), Sergio Lira (New York, NY)*

01.45 pm – 02.15 pm  
Scleroderma  
*Thomas Krieg (Cologne, Germany)*
02.15 pm – 02.45 pm  Lupus – Pathogenic and therapeutic advances  
Virginia Pascual (Dallas, TX)

02.45 pm – 03.15 pm  Chronic urticaria and IgE targeting  
Marcus Maurer (Berlin, Germany)

03.15 pm – 03.45 pm  COFFEE BREAK

Chairs: Brian J. Nickoloff (Carmel, IN), Zahi A. Fayad (New York, NY)

03.45 pm – 04.15 pm  Chances and hurdles of investigator initiated trials  
Alexander Navarini (Zurich, Switzerland)

04.15 pm – 04.45 pm  Unmet needs – Defining research frontiers  
Michael D. Howell (Gaithersburg, MD)

04.45 pm – 05.15 pm  The translational revolution – Implications for the health care system  
Mark Lebwohl (New York, NY)

05.15 pm – 05.45 pm  From target discovery to therapeutic development  
George D. Yancopoulos (Tarrytown, NY)

05.45 pm – 06.00 pm  CLOSING SESSION & FAREWELL
Industry Supported Sessions

Complimentary CME Symposium

WEDNESDAY, NOVEMBER 16, 2016  5:15 PM - 6:45 PM  Hosack Hall

“Inflammation: More Than Skin Deep in Psoriasis”
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

5:15 pm – 5:20 pm  Introductions and Overview of Systemic Inflammation
James G. Krueger, MD, PhD

5:20 pm – 5:35 pm  Clinical Significance of Cardiometabolic Comorbidity in Psoriatic Disease
Joel M. Gelfand, MD, MSCE

5:35 pm – 5:50 pm  Pathogenic Mechanisms Linking Inflammatory Disease to Adverse Cardiometabolic Outcomes
Iain B. McInnes, FRCP, PhD, FRSE

5:50 pm – 6:05 pm  Current Treatment Paradigms of Moderate to Severe Psoriasis
Joel M. Gelfand, MD, MSCE

6:05 pm – 6:20 pm  Current Treatment Paradigms of Psoriatic Arthritis
Iain B. McInnes, FRCP, PhD, FRSE

6:20 pm – 6:35 pm  Translating Pathways to Clinical Cases
Joel M. Gelfand, MD, MSCE & Iain B. McInnes, FRCP, PhD, FRSE

6:35 pm – 6:45 pm  Questions and Answers

Complimentary Non-CME Symposium

THURSDAY, NOVEMBER 17, 2016  8:00 AM - 9:30 AM  Room 20

“Targeted mAb Therapies: Learning from the Past to Drive Innovation”
AbbVie sponsored Symposium

8:00 am – 8:15 am  Introduction
James Krueger, D. Martin Carter Professor in Clinical Investigation, The Rockefeller University
8:15 am – 8:35 am  Through the Looking Glass of Targeted mAb Therapies
Maureen Kelly, Group Medical Director, Pharmaceutical Development, AbbVie

8:35 am – 9:00 am  Therapeutic Targeting of the IL-23 Axis: The Central Role of IL-23 in Psoriasis
James Krueger, D. Martin Carter Professor in Clinical Investigation, The Rockefeller University

9:00 am – 9:20 am  Engineering Therapeutic Antibodies – The Relationship of Structure to Function
Paul Tebbey, Therapeutic Area Lead, Biotherapeutics and Gastroenterology, US Medical Affairs, AbbVie

9:20 am – 9:30 am  Q&A/Summary

Complimentary Non-CME Symposium

THURSDAY, NOVEMBER 17, 2016  12:45 PM – 2:15 PM  Room 20

“Pathways to Personalized Medicine in Dermatology”
Speakers: Emma Guttman, MD, PhD & John Armstrong, PhD, Galderma Rx Strategic Programs
Galderma sponsored Symposium

Agenda: Please see separate brochure.

Complimentary CME Symposium

FRIDAY, NOVEMBER 18, 2016  12:15 PM– 1:45 PM  Hosack Hall

“New Frontiers and Clinical Advances in the Pathoimmunobiology of Atopic Dermatitis”
Funded by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

12:15 pm – 12:30 pm  The Disease Burden of Atopic Dermatitis: The Unmet Need for New Therapies in Patients with Moderate-to Severe and/or Resistant AD–The Rationale and Necessity for Intervening in the Atopic March and Mitigating the Risk of Co-Morbid Conditions
Emma Guttman, MD, PhD
12:30 pm – 12:55 pm  Currently Established and Emerging Therapies for Managing Patients Across the Disease Continuum of Atopic Dermatitis: From Topical to Systemic Therapies—Guideline-Focused Sequencing Strategies From the AD Toolkit  
Mark Lebwohl, MD

12:55 pm – 1:15pm  The Pathoimmunobiology of Atopic Dermatitis: Translating Advances in Immunoscience into Actionable Pharmacologic Targets for Treatment of Inflammatory Disorders of the Skin  
Emma Guttman, MD, PhD

1:15 pm – 1:40 pm  From Evidence to Clinical Action: Results and Translational Implications of Landmark Trials in Atopic Dermatitis: What Do the Trials Teach Us? What Are The Translational Implications for the Front Lines of Dermatology Practice?  
Lisa A. Beck, MD

1:40 pm – 1:45 pm  Question & Answer Session/Faculty Roundtable

Complimentary CME Symposium

FRIDAY, NOVEMBER 18, 2016  4:00 PM – 5:30 PM  Hosack Hall

“Considerations for Future Treatment of Inflammatory Skin Disease: Immune Regulation, Cutaneous Tolerance, and T-cell Plasticity”  
James G. Krueger, MD, PhD; Michael D. Rosenblum, MD, PhD; Vijay K. Kuchroo, PhD  
Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. and Novartis Pharmaceuticals Corporation

4:00 pm - 4:10 pm  Introduction: Tolerance, Immune Regulation, and Disease Interception

4:10 pm - 4:40 pm  Tregs, Immune Regulation in the Skin, and Tolerance

4:40 pm - 5:10 pm  T-cell Plasticity: A Focus on Th-17 T-cells

5:10 pm - 5:30 pm  Q & A
Complimentary CME Symposium

SATURDAY, NOVEMBER 19, 2016 8:30 AM - 10:00 AM Hosack Hall

“Advances in Atopic Dermatitis: Expert Insights Into New and Emerging Therapies”
This activity is supported by an educational donation provided by Anacor Pharmaceuticals, Inc.

8:30 - 9:00 am  Registration
9:00 - 10:00 am Clinical Program
Amy S. Paller, MD

- Epidemiology and Comorbidity
- Pathophysiology
- Diagnosis and Assessment
- Treatment Guidelines
- Current Topical Approaches: Mild to Moderate Disease
- Current Systemic Approaches: Severe AD
- Emerging Therapies
- Summary
- Q & A
Jointly provided
by the Kimberly and Eric J. Waldman Mount Sinai
Department of Dermatology
and the Austrian Academy of Sciences.

www.isds2016.org